NasdaqCM - Delayed Quote USD

Celularity Inc. (CELU)

2.0400
+0.0500
+(2.51%)
At close: 4:00:01 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
54,220
54,220
22,771
17,975
21,335
Cost of Revenue
14,989
14,989
16,016
19,665
9,653
Gross Profit
39,231
39,231
6,755
-1,690
11,682
Operating Expense
77,782
77,782
83,234
146,577
161,886
Operating Income
-38,551
-38,551
-76,479
-148,267
-150,204
Net Non Operating Interest Income Expense
-5,933
-5,933
-2,695
365
-2,839
Other Income Expense
-13,408
-13,408
-117,111
162,107
52,945
Pretax Income
-57,892
-57,892
-196,285
14,205
-100,098
Tax Provision
0
0
10
13
20
Net Income Common Stockholders
-57,892
-57,892
-196,295
14,192
-100,118
Diluted NI Available to Com Stockholders
-57,892
-57,892
-196,295
14,192
-100,118
Basic EPS
-2.64
--
-11.02
1.01
-14.90
Diluted EPS
-2.64
--
-11.02
0.95
-14.90
Basic Average Shares
21,890.5180
--
17,813.0440
13,990.7030
6,705.7270
Diluted Average Shares
21,890.5180
--
17,813.0440
14,983.0020
6,705.7270
Total Operating Income as Reported
-38,358
-38,358
-192,287
-25,600
-109,059
Total Expenses
92,771
92,771
99,250
166,242
171,539
Net Income from Continuing & Discontinued Operation
-57,892
-57,892
-196,295
14,192
-100,118
Normalized Income
-54,575
-54,575
-109,676.2400
-150,584
-154,745
Interest Income
331
331
320
365
332
Interest Expense
6,264
6,264
3,015
0
3,171
Net Interest Income
-5,933
-5,933
-2,695
365
-2,839
EBIT
-51,628
-51,628
-193,270
14,205
-96,927
EBITDA
-43,706
-43,706
-183,946
23,641
-88,110
Reconciled Cost of Revenue
8,820
8,820
8,885
12,422
3,028
Reconciled Depreciation
7,922
7,922
9,324
9,436
8,817
Net Income from Continuing Operation Net Minority Interest
-57,892
-57,892
-196,295
14,192
-100,118
Total Unusual Items Excluding Goodwill
-3,317
-3,317
-109,644
164,776
54,627
Total Unusual Items
-3,317
-3,317
-109,644
164,776
54,627
Normalized EBITDA
-40,389
-40,389
-74,302
-141,135
-142,737
Tax Rate for Calcs
0
0
0.0002
0
0
Tax Effect of Unusual Items
0
0
-23,025.2400
0
0
12/31/2021 - 8/8/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SRNE Sorrento Therapeutics, Inc.
0.0011
0.00%
 
IPSC Century Therapeutics, Inc.
0.5600
+8.23%
 
AARD Aardvark Therapeutics, Inc.
9.89
+8.80%
 
AVTX Avalo Therapeutics, Inc.
3.9100
+1.30%
 
VINC Vincerx Pharma, Inc.
0.0500
0.00%
 
ABP Abpro Corporation
0.2300
-13.24%
 
BDTX Black Diamond Therapeutics, Inc.
1.9500
+1.04%
 
ITOS iTeos Therapeutics, Inc.
7.81
-2.01%
 
XLO Xilio Therapeutics, Inc.
0.8594
+7.42%
 
KAPA Kairos Pharma, Ltd.
0.6210
+0.98%